LUME-Lung 1 trial - Dr. Anders Mellemgaard
Dr. Anders Mellemgaard, Department of Oncology, Herlev University Hospital, Copenhagen.
The LUME lung 1 trial was designed to examine the role of nintedanib added to the standard therapy of docetaxel for patients with advanced non- small cell lung cancer in second-line treatment.
Listen to Dr. Mellemgaard to hear more about the trial results.
Footnotes
*Nintedanib is an investigational compound and is not yet approved. Its safety and efficacy have not yet been fully established.